durabl growth trajectori
last week host meet thermo fisher across europ ever
believ thermo fisher custom valu proposit reson
market thermo fisher strategi incred consist leverag compani
strength scale portfolio breadth drive custom success maxim
growth potenti compani addit follow period major
consolid believ compani portfolio tilt toward faster growth
trajectori evidenc organ growth ttm thermo fisher steadi
leadership effect strategi cultur give us convict durabl
futur growth rais price thank cfo
stephen williamson ir ken apicerno host meet us
 differenti biopharma strategi reson thermo fisher outlook
biopharma end market remain posit believ compani uniqu mix
higher growth asset posit well durabl growth lot
convict thermo fisher abil deliv least m-hsd end market growth
especi favor bioproduct comp favor biopharma
servic comp
 fei highlight franchis advantag electron microscopi thermo fisher
continu messag posit outlook electron microscopi compani
benefit super-cycl semiconductor custom
make progress develop new life scienc platform expand reach
 cascadion highlight franchis advantag dx think thermo fisher
innov cascadion clinic mass spectrometri great exampl
compani drive uniqu product offer custom thermo fisher note
expect revenu build toward end
 china local strategi take outsiz share china continu strong
contributor growth thermo fisher note growth broad
base confid near-term outlook discuss trade
tariff remain topic thermo fisher see materi impact oper
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight thermo fisher market leader
across divers portfolio life scienc tool
diagnost impress global reach across
custom class end market compani
consist track record organ growth capit
deploy manag execut
recommend share core hold exposur
innov healthcar
see upsid thermo fisher target driven
continu biopharma strength well futur
capit deploy upsid case reflect
upsid ep
thermo fisher exposur econom activ
end market could impact growth
specif industri end market repres
around revenu downsid case
reflect downsid ep
action rais pt valuat attract price-to-earnings
differenti biopharma strategi reson
fei highlight franchis advantag electron microscopi
cascadion highlight franchis advantag dx
china local strategi take outsiz share
channel busi durabl growth strategi
capit deploy consist prefer fragment industri
trajectori believ set-up posit
busi cyclic defens downturn
odd end custom penetr end market elect exposur mass
last week host meet thermo fisher across europ ever
believ thermo fisher custom valu proposit reson market
thermo fisher strategi incred consist leverag compani strength
scale portfolio breadth drive custom success maxim growth
potenti compani addit follow period major consolid believ
compani portfolio tilt toward faster growth trajectori evidenc
organ growth ttm thermo fisher steadi leadership effect strategi
cultur give us convict durabl futur growth rais price
thank cfo stephen williamson ir ken apicerno
host meet us
action rais pt valuat attract price-to-earnings
rais price thermo fisher given increas
convict compani strategi near-term outlook term model
modestli rais ep forecast build bd advanc bioprocess
acquisit expect close earli valuat new price target
repres new ep forecast previous note
thermo fisher current trade ep one-year price target simpli
appli multipl forward year result prior price target
repres prior ebitda forecast
given thermo fisher optim balanc sheet leverag believ price-to-earnings better
metric valuat comparison versu broader set peer wherea prefer
ev/ebitda life scienc tool peer under-lev see number
similar thermo fisher busi model industri within consum
higher growth name organ growth carri higher multipl would
argu price-to-earnings basi share great rel valu compar tool peer
get better idea thermo fisher stack compar compani
cover barclay analyst lauren lieberman pack food cover andrew
lazar chart includ sever compani sector
specif focu comparison versu compani expect grow organ
revenu compound-annual-growth-rate least look organ revenu growth
adjust ep growth gross margin ebit margin dividend yield leverag debt-to-
five-year period thermo fisher outperform
higher growth compani within consum sector respect organ
revenu adjust ep growth compani grown organ revenu
compound-annual-growth-rate higher consum sector averag
time period compani grew adjust ep faster compar comp
group addit compani expect modestli outperform
consum sector compani project thermo fisher grow
ep compound-annual-growth-rate exclud
includ debt paydown share
repurchas higher expect growth rate consum
compani expect compani lower gross margin
modestli lower ebitda margin thermo fisher leverag well
consum sector
despit thermo fisher out-performance rel higher-growth consum
sector compani compani trade discount comp group
price-to-earnings basi note one explan thermo fisher lower multipl could
dividend yield averag yield consum stock
analysi explan could gross margin
consum compani said dont believ modestli weaker margin lower
valuat ultim believ rel out-performance thermo fisher
warrant valuat similar compani within consum sector
thermo fisher comp rel consum peer
note organ growth exclud adjust ep exclud pf total revenu ep gross margin ebitda margin
dividend yield base consensu organ revenu price-to-earnings multipl base barclay estim price
look valuat rel life scienc tool peer thermo fisher cheapest
compani coverag list price-to-earnings basi believ compani trade
discount reason believ investor risk-adjust thermo fisher
tax rate though would argu us tax reform put compani equal foot
thermo fisher treasuri team strateg advantag peer like
level premium embed valuat thermo fisher higher level deal
amort adjust non-gaap result though compani adjust
companytickerorgan growth compound-annual-growth-rate growth compound-annual-growth-rate growth compound-annual-growth-rate growth compound-annual-growth-rate gross ebitda leverag debt-to-capitaldividend price-to-earnings mutliplethermo sector sector beverag coca-cola coor foodb hershey smucker cosmet household careavon este lauder flavor classifi higher growth organ growth barclay thermo fisher scientif inc
price-to-earnings life scienc tool
cy ev ebitda life scienc tool
detail state
biopharma end market
pleas see report
differenti biopharma strategi reson
thermo fisher outlook biopharma end market remain posit
believ compani uniqu mix higher growth asset posit well
durabl growth pharma biotech custom thermo fisher largest end
market repres compani revenu base believ evolv
strategi mix biopharma product play directli thermo fisher
strength help drive mid-teen end market growth underli
environ remain healthi driven sever factor includ
need invest face patent cliff new opportun term innov
precis medicin accommod regulatori environ new drug approv
market leader laboratori product servic thermo fisher give custom
consist supplier research transit across academia biotech larger
pharmaceut sponsor lot convict thermo fisher abil deliv
least m-hsd end market growth especi favor bioproduct comp
favor biopharma servic comp due hurrican maria impact
puerto rico patheon site
thermo fisher uniqu offer start compani biopharma servic
busi offer clinic trial logist well contract develop
manufactur servic patheon collect busi repres
around thermo fisher revenu believ grow least high-
singl digit macro level pharmaceut compani manag complex suppli
chain face regul reimburs pressur thermo fisher believ
biopharma servic offer aggreg share trust supplier strateg
custom relationship c-suit sponsor custom face differ issu
logist manufactur servic increasingli outsourc given
sponsor simpli adequ capabl hous overal biopharma servic
busi run former patheon michel legard part thermo fisher
get differenti custom access c-suit head
manufactur sponsor wherea previous patheon would often interact lower
level execut organ thermo fisher interest enter cro
industri compani believ cro skill set match well
compani capabl would compet custom directli
much thermo fisher market compani want leader industri
would difficult achiev given entrench particip cro industri
clinic trial logist busi rev offer packag procur cold
chain logist increasingli outsourc drive effici thermo fisher note
custom valu servic evidenc recent growth excess compani
averag well margin compani averag follow septemb
acquisit patheon rev thermo fisher offer integr offer
servic span formul develop api/finish dosag form
manufactur see diagram formul servic offer help custom
determin appropri method deliv drug bodi patheon help
custom scale api finish dosag form manufactur follow
molecul clinic develop commerci thermo fisher expect
balanc futur invest busi across organ invest custom site
acquisit well acquisit exist cdmo patheon current footprint
manufactur site focus biolog steril manufactur
organ cfo williamson highlight compani invest st loui
site addit biolog capac well invest capac expans
germani clinic trial logist
addit thermo fisher bioproduct franchis rev offer upstream
tool consum need manufactur larg molecul therapeut given
increas invest asset biopharma sponsor believ
franchis durabl double-digit growth trajectori least next decad
drug substanc api analyt method developmentpart develop servicesclin trial logisticspre-formulationformul developmentscale-up transferclin batch manufacturingpre-clin testingphas iphas iiphas iiiregistrationapprovalcommerci manufacturingindndaotherclin trial logist barclay thermo fisher scientif inc
natur synergi leverag thermo fisher bioproduct asset
biopharma servic engin given compani relationship biotech custom
compani goal get specd earli follow custom clinic
develop commerci thermo fisher largest provid
upstream technolog includ cell media singl use technolog compani
ad scale busi acquisit ad
busi acquisit finess recent thermo fisher
announc plan acquir bioprocess asset becton dickinson
cover add addit franchis
within life scienc tool coverag bioproduct one fastest grow
area within life scienc tool coverag big barrier entri structur
tailwind provid least decad runway growth bioproduct repres
manufactur process larg molecul drug includ biolog biosimilar
vaccin gene therapi car-t therapi ultim believ thermo fisher
strong biopharma relationship posit compani well bioproduct believ
success biopharmaceut ultim depend process equip
use manufactur therefor supplier agreement tend direct made
higher level organ beyond popul growth age demograph
see number driver support growth competit moat
growth within biolog iqvia estim global biolog market grow
annual billion
biosimilar growth opportun believ gener form biolog known
biosimilar drive market expans bioproduct
rel lower price product could increas demand therapeut addit
new manufactur enter market expand demand suppli
access healthcar emerg market growth emerg market expect
continu driver larg molecul drug iqvia institut estim
outlook global medicin pharmerg economi grow
medicin volum usag annual next year versu us
regul given complex natur produc larg molecul drug
manufactur process highli regul manufactur activ written
fda approv sponsor reluct switch vendor given
inher add unneed uncertainti process
full thought
exposur pleas see report
biopharma
 long outlook
among life scienc tool peer believ thermo fisher uniqu capabl serv
biopharma end market under-appreci serv long-term
differenti growth driver compani altogeth biopharma end market
repres around thermo fisher revenu grown least m-hsd
includ mid-teen compani foundat start research capabl
channel busi consolid histor driven growth thermo
fisher aggreg client wallet thermo fisher capabl product
qa/qc continu perform well global access therapeut drive demand liquid
chromatographi beyond thermo fisher uniqu capabl repres around
revenu includ contract drug manufactur patheon clinic trial
logist collect biopharma servic busi well bioproduct asset
see sustain long-term growth driver hsd-low-teen segment
believ long-term structur tailwind support visibl import
growth driver thermo fisher
thermo fisher uniqu biopharma exposur repres revenu mm
fei highlight franchis advantag electron
thermo fisher continu messag posit outlook electron microscopi
compani benefit super-cycl semiconductor custom
make progress develop new life scienc platform expand
reach technolog remind thermo fisher complet fei acquisit
septemb billion give market lead capabl electron
microscopi year acquisit team done effect job
scale busi given robust market condit cfo williamson note
compani expand capac doubl product volum fei also benefit
thermo fisher scale build servic network sinc extern
electron microscopi servic peopl compani hire transit intern
mass spec/chromatographi servic peopl fei train backfil
role addit extern hire final thermo fisher note approxim
fei expens base benefit compani scale procur
term demand compani note wait list system research
custom increasingli adopt system order keep latest advanc
scienc fact team nobel prize chemistri base
ttm result thru total trial total total biopharma total fisher biopharma contribut organ growthrevscdmo -patheonorgan growthrevsclin trial logisticsorgan growthrevsbioproductionorgan growth barclay thermo fisher scientif inc
look forward thermo fisher prioriti find way innov electron
microscopi better democrat system life scienc research custom life
scienc research custom repres rel small portion fei revenu today
around import growth driver compani natur
pathway improv instrument size cost eas use penetr custom
base one rational thermo fisher announc acquisit gatan
june gatan supplier camera filter softwar use
manufactur electron microscopi own supplier allow thermo fisher better
optim workflow piec togeth order get better specif
product tool natur cross-sel electron microscopi
thermo fisher expertis mass spectrometri well structur biolog
match protein structur mass spectromet visual use cryo-em
believ would power combin research believ
fei acquisit great exampl thermo fisher consolid activ
offer compel valu proposit custom
analyt instrument recent growth leader thermo fisher
detail
cascadion launch see
report august
cascadion highlight franchis advantag dx
think thermo fisher innov cascadion clinic mass spectrometri
anoth great exampl compani franchis advantag drive uniqu
product offer custom within compani budget compani
work blue sky project could drive new opportun compani
custom given compani portfolio breadth believ thermo fisher uniqu
posit drive new innov across busi line peer cant match cascadion
clinic mass spectrometri platform mark thermo fisher first foray
routin test area histor mass spectrometri advanc sensit
platform use routin test isol special test area
toxicolog test cascadion system offer simpl sample-in answer-out
solut custom walkaway system allow limit hand time
simplifi workflow enabl routin adopt clinic lab thermo fisher
work platform year remain excit
opportun platform earn ce-mark earlier year intern launch
earli stage compani continu expect fda approv platform
launch limit menu work expand given time thermo
fisher note expect revenu build toward end
feedback beta custom posit compani work
close year make sure optim instrument term
size compani continu note difficult one product
materi thermo fisher overal though certainli expect cascadion
addit compani specialti diagnost segment growth overal
revenu compani still evalu whether pursu reagent rental vs capit
sale approach custom mix thereof though ultim agnost either
approach expect consumable-heavi platform gener consist revenu
head-to-head analysi clinic mass spec offer
china local strategi take outsiz share
china continu strong contributor growth thermo fisher believ
compani local strategi exemplifi custom valu proposit allow
compani take outsiz share custom china lead sourc
growth compani highlight growth vs organ growth
overal china nation ambit countri includ focu life
scienc research expand access healthcar countri popul resolv
long-term societ issu food air water qualiti countri depend
import technolog achiev goal life scienc research
academ biopharma sponsor want work view credibl global
commun order export futur product global exampl difficult us
see fda would approv chines therapeut werent develop use
manufactur protocol possibl local competitor could revers
engin product thermo fisher sell theyr abl resolv applic
could ultim compromis scienc local custom
govern will pay highest qualiti technolog thermo fisher
note growth broad base region confid near-
term outlook cours certainli possibl countri could pull back
invest broader market issu compani see right
thermo fishersciex instrument namecascadion smtopazintern vitamin fda-approv initi assay menuvitamin total testosteron immunosuppress drugsvitamin tbdtest minopen close close fda-approv content open fda-approv content sampl per hourn/asampl reagent tube insert de-cap tube barcod face outmor step even recent insert sampl rack barcod reader scan li queriedautom hit start button analysi begin result feed li barclay thermo fisher scientif inc
addit thermo fisher local approach appear reson thermo fisher
view local competitor china revenu billion region
oper ground year compani describ china
organ head manufactur head head financ
chines citizen fact compani employe region
ex-pat thermo fisher deploy deep govern relat effort
senior manag visit region multipl time year meet variou
branch govern level thermo fisher believ compani scale
matter china market given custom prefer holist
buy interestingli thermo fisher china busi larger hand
compani pure-play competitor compani abil bundl servic custom
appear drive share gain
discuss trade tariff remain topic thermo fisher see
materi impact oper continu believ thermo fisher life
scienc tool coverag sweet spot amidst trade tension us
china countri depend import technolog help address
nation challeng life scienc tool technolog mostli
immun polit debat thu far cfo williamson reiter gross basi
tariff would impact ep annual net basi
would neutral price suppli chain action fact certain life scienc
tool categori initi target tariff remov list sinc china
recogn would simpli tax good
compani export china us though manufactur china
china suppli chain price offset adjust manag
situat compani note chang region relat
custom demand product face tariff part
discuss custom compani confid recent region growth
relat inventori build custom thermo fisher primarili sell direct china
sell dealer visibl custom ultim inventori
thermo fisher china busi alon similarli size
larger rel peer ttm rev mm
china repres thermo fisher rev ttm
thermo fisher region growth quarter
channel busi durabl growth strategi
thermo fisher note price competit environ across
healthcar research channel busi remain consist thermo fisher
largest supplier distributor laboratori product given legaci root fisher
scientif merger thermo electron fisher scientif creat combin
entiti uniqu industri term scale self-manufactur product
product set core thermo fisher custom valu proposit difficult
peer replic thermo fisher continu benefit posit price rang
across entir portfolio compani price team done effect
job manag market challeng fx higher inflat
thermo fisher see increment competit amazon cover
ross sandler continu invest extend leadership custom
view thermo fisher amazon life scienc thermo fisher advantag start
breadth compani offer subsequ relev custom
million sku catalog thermo fisher critic vendor custom
fact compani note sever top custom thermo fisher actual
largest extern spend sourc third largest bucket behind labor facil
expens around channel sale self-manufactur vs third parti give
compani control way product distribut custom thermo
fisher continu invest e-commerce capabl on-line content way
improv valu proposit custom natur lab product servic
growthldd growthlow-teensldd growthldd growthhsd growthldd growthlow-teensmid-teenslow-teenschinahigh-teensmid-teenshigh-teensstrong growthnorth americamsd growthlsd growthlsd growthlsd growthlsd growthhsd growthlsd growthmsd growtheuropemsd growthlsd growthlsd growthmsd growthmsd growthlsd growthmsd growthmsd growthmsd growthhsd growthrowhsd declinemsd declinelsd declinelsd declineflatflatmsd growthlow-teensmsd growthlow-teensceo marc casper let make quick comment overal perform geograph perspect saw good condit end market across globe continu strong momentum china better growth quarter strength global competit posit coupl strong market condit great execut team led excel growth second element growth strategi leverag scale emerg high growth market mention earlier saw continu strength across geographi highlight china deliv anoth outstand quarter strategi leverag unmatch scale depth capabl along great tactic execut enabl us take full advantag mani growth opportun set us well help custom china meet object outlin countri five year plan let talk first china perform talk littl bit tariff busi perform extrem well growth quarter first half strong momentum broad-bas across variou custom set begin quarter look forward go back littl later year one thing custom base bullish outlook thing see paper trade thing sort realli dialog amongst custom base custom base realli business-as-usu market strong mid-singl digit growth quarter good good condit academ fund good realli see dramat pocket weak fact rel last number year strong mid-singl digit growth actual realli nice spot domest perspect realli see anyth meaning weak side cfo stephen williamson look growth geographi marc mention market strong across globe america grew mid-singl digit europ grew high-singl digit asia pacif grew low-teen includ anoth quarter strong growth china rest world also grew low-teen barclay thermo fisher scientif inc
detail thermo
see note may
underappreci art
deal
research custom util also provid barrier entri thermo fisher
thermo fisher abil handl complex/hazard good well product
requir continu cold chain final import note thermo fisher
custom base unwil compromis qualiti research need
biopharma custom invest research discov target could becom
basi novel therapeut academ custom fund grant invest
research ultim could get publish peer review journal ultim
potenti save modest amount money unnecessari risk given research risk
trade-off cours thermo fisher argu price disadvantag custom
order amazon given thermo fisher price model provid discount
certain level volum beyond amazon compani note competit
ration major chang merger activ taken place
past sever year
capit deploy consist prefer
thermo fisher capit deploy strategi remain consist compani
consolid consolid industri expect particip consolid
time thermo fisher philosophi predic around compani custom
valu proposit thermo fisher focus drive scale relev custom
enabl success either better product suit custom innov
need thermo fisher drive coordin across busi gener strong cash
flow re-deploy continu drive growth compani
consider pursu whether custom find thermo fisher
acquisit valuabl earn appropri financi return
compani note lot capac futur doesnt want drive
consolid consolid sake compani continu re-invest
busi capital-expenditure first beyond primari focu thermo fisher
note need futur deal though obvious
compani primari focu run busi well use custom valu
proposit ppi drive growth
thermo fisher describ compani approach sourc monitor
target dub project univers compani four busi segment
sub-divid busi unit gener manag busi
task invest thesi around compani current mix asset
direct want take portfolio time part plan
process also respons look new invest refresh
product portfolio thermo fisher execut stay close compani
interest asset come avail compani readi negoti
discuss potenti exit strategi thermo fisher host monthli inorgan growth
board walk though compani target opportun action
strateg process also understand compani busi
expand intern resourc invest need corpor level execut
scout deal cut across compani busi segment compani
invest thesi almost compani industri react quickli
target becom avail deal process begin dilig around confirm
slightli chang thesi compani alreadi thermo fisher regularli
perform post mortem acquisit get tag deal life
compani order ensur involv someth goe wrong asset
thermo fisher maintain long-term wacc deal despit fact
actual cost capit well larger deal compani challeng
better understand potenti downsid risk acquisit action
compani take earn decent minimum return time period speed
size return inform thermo fisher oper asset day order
minim downsid maxim upsid term leverag compani
comfort ad debt jeopard invest grade rate thermo
fisher note gone leverag past deal track record
give rate agenc comfort around abil return normal level time
compani like bbb rate debt allow benefit invest grade
financ cost well flexibl drive consolid industri
thermo fisher histor deal stock perform close mm
trajectori believ set-up posit
piec togeth thesi believ thermo fisher well track achiev
compani long-term target near-term momentum improv visibl
compani long-term guidanc call organ growth predic
market growth least share gain annual thermo fisher
oper higher end rang includ organ growth
past year attribut combin end market oper strength
well compani take signific share custom biggest risk around
market growth though end market tracker continu screen quit posit
compani cyclic end market fei semiconductor custom though
momentum cryo-em applic remain strong moment fx would
current repres around headwind revenu one swing factor
compani watch close brexit uk pound exposur margin
annual organ expans appear achiev along capit deploy
effect tax manag long-term ep growth appear reason
compani acquiredd announcedd closedtim closed equiti sizeacquir revstmo prev revsrel sizetmo return closeexcess return vs pcost synergiesrev op inc total synergi acq revskendro lab barclay thermo fisher scientif inc
pleas see report
nice fei
pleas see report
thought acquisit
bd
believ recent announc alreadi could add around ep growth
help thermo fisher deliv long-term commit
ep growth year date thermo fisher announc deploy
toward two tuck-in deal gatan bioprocess busi view
new ep forecast potenti conserv repres
growth y/i consensu current
 gatan thermo fisher announc acquisit gatan
subsidiari roper cover julian mitchel gatan manufactur instrument
softwar use manufactur electron microscop natur make gatan
import supplier alreadi fei market leader electron microscopi
estim fei repres gatan annual sale base
market share data thermo fisher recogn immedi cost save benefit
fei busi gatan also gener ebitda extern parti
transact expect complet end
 bd bioprocess thermo fisher announc acquisit
becton dickinson cover bioprocess asset busi provid technic
servic pepton enhanc cell cultur media natur fit thermo fisher
upstream bioproduct offer cell cultur media single-us technolog
asset gener around million revenu estim around million
ebitda assum asset gener similar margin thermo fisher
bioproduct busi today modestli lss averag
transact expect close earli
busi cyclic defens downturn
natur question go wrong defens portfolio
downturn addit post differenti growth also view thermo fisher
portfolio quit defens thermo fisher manag focus drive strong
execut regardless market condit long-term organ growth
rang follow financi crisi thermo fisher revenu declin ep also
declin said compani portfolio mix much
defens higher exposur recur revenu less exposur cyclic
industri market sinc recur revenu increas
industrial/appli exposur decreas
market issu think thermo fisher leverag durabl
busi model financi flexibl take share custom thermo fisher
paranoid complac focus support custom relationship
new product vital maintain momentum compani note
market issu thermo fisher strategi step-up intern program area
deliv quick payoff emerg downturn posit competit
strength durabl compani growth allow continu invest
competitor may cut back protect earn profil
mix revenu end market
mix revenu product type
ttm mix revenu end market
ttm mix revenu product type
odd end custom penetr end market
penetr top custom believ thermo fisher signific scale
strateg relationship compani largest custom major competit
advantag compani amongst compani top custom thermo fisher
biggest area spend outsid headcount facil expens con
obvious custom want best price risk issu
one area thermo fisher busi could put risk entir strateg relationship
custom said natur strateg relationship give thermo
fisher visibl full level invest spend custom
allow thermo fisher help product innov need
drive growth compani estim top custom
strateg basi custom compani largest custom
revenu penetr term thermo fisher could
look sole compani product offer despit advantag
thermo fisher custom relationship strateg natur point
also remain opportun compani continu deploy custom
valu proposit drive growth
academ end market outlook continu look posit academ research
custom global basi unit state nih area continu
invest polit parti find agreement invest life
scienc research yield innov save healthcar system
longer term addit european invest improv german invest
improv uk commit research invest even brexit
broadli europ transit horizon horizon europ creat
new invest program research final asia research invest
strong contributor end market perform especi china compani
embark nation initi creat research hub compet
us mid-term elect thermo fisher believ compani industri
rel isol upcom mid-term elect regardless outcom
congress bipartisan support nih fund continu
growth contributor compani
gener sequenc though franchis repres
revenu natur remain signific interest thermo fisher ambit
compani intend compet clinic market thermo fisher
strategi remain unchang compani focus clinic applic
oncolog ion torrent franchis green-field opportun sever
competit differenti compani platform make thermo fisher
specif believ thermo fisher biopharma
relationship competit advantag field companion diagnost cdx
thermo fisher earn first-ev fda approv kit panel
compani oncomin panel develop partnership novarti
addit abil technolog work small sampl size vs sb
chemistri could advantag work tumor sampl thermo fisher
aspir compet research market whole genom illumina
sb chemistri major competit advantag research custom thermo
fisher recogn invest better target clinic market
mass spectrometri thermo fisher continu feel good compani
prospect mass spectrometri compani strength proteom orbitrap
relev research precis medicin genet
strong long-term tailwind thermo fisher focus continu advanc
scienc drive collabor compani custom thermo fisher
believ mass spectrometri area take share stand-alone
competitor given contrast compani result vs report peer
note tool average includ agil lsag acg bruker bsi da water divis
vision final thought worthwhil conclud thought
thermo fisher vision thermo fisher unveil vision first
time analyst day compani aspir unriv leader
serv scienc one world admir compani concept
simpl compani perform driven enabl success
custom employe sharehold includ drive organ growth
innov pioneer new area scientif research custom well
expand technolog servic capabl compani also
focus drive growth digit platform util data inform
differ way enabl greater custom product extern mean
right compani custom launch right product drive innov
support sharehold valu cfo williamson note still year
away compani focus deliv quarter robust perform
deliv object
estestestestestestestestestestincom statement growth growth growth organ adj product product product revenu inc servic servic gross margin inc sg stock comp total sg product margin oper incom margin improv w/ improv annual bs annual bs debt item expens pre-tax tax benefit net averag sharesbas ep continu opsbas adj adj full-year barclay thermo fisher scientif inc
thermo fisher statement flow
estestestestestestestestesteststat activitiesnet discontinu dispos discontinu continu defer incom gain sale stock-bas interest expens convert benefit stock-bas comp charg sale non-cash expens work capitalaccount retir chang work cash provid continu cash use discontinu oper growth net activitiesacquisit net cash growth sale available-for-sal sale sale retir note increas restrict deriv invest activ use discontinu invest cash use invest activitiesnet proce issuanc long-term commerci paper convert long-term short-term note per proce issuanc proce issuanc employe benefit stock-compens financ activ cash provid financ rate effect equival equival growth adj net debt ttm barclay thermo fisher scientif inc
estestestestestestestestestestbal sheet asset cash receiv less allow tax current current less accumul intang asset payrol employe incom accru current incom long-term convert debt sharehold liabil barclay thermo fisher scientif inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
